Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-06-02	Premium	bought	Premium	Premium	Premium	-
2022-11-28	Premium	acquired	Premium	Premium	Premium	-
2022-11-25	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2022-11-23	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2022-11-22	Premium	acquired	Premium	Premium	Premium	-
2022-11-17	Premium	acquired	Premium	Premium	Premium	-
2022-11-15	Premium	acquired	Premium	Premium	Premium	-
2022-10-26	Premium	acquired	Premium	Premium	Premium	-
2022-10-21	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2022-10-17	Premium	bought	Premium	Premium	Premium	-
2022-10-17	Premium	acquired	Premium	Premium	Premium	-
2022-09-06	Premium	bought	Premium	Premium	Premium	-
2022-09-02	Premium	bought	Premium	Premium	Premium	-
2022-09-01	Premium	bought	Premium	Premium	Premium	-
2022-08-30	Premium	bought	Premium	Premium	Premium	-
2022-08-29	Premium	bought	Premium	Premium	Premium	-
2022-08-19	Premium	bought	Premium	Premium	Premium	-
2022-08-17	Premium	bought	Premium	Premium	Premium	-
2022-06-29	Premium	acquired	Premium	Premium	Premium	-
2022-06-28	Premium	acquired	Premium	Premium	Premium	-
2022-06-27	Premium	acquired	Premium	Premium	Premium	-
2022-06-23	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2022-06-23	Premium	acquired	Premium	Premium	Premium	-
2022-06-21	Premium	acquired	Premium	Premium	Premium	-
2021-12-20	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer

KTTA - Pasithea Therapeutics Corp. Stock Price, Fair Value and News

Latest Insider Trading transactions for KTTA